Trial of Gene Therapy for Sickle Cell Disease Halted
Therapy developer Bluebird Bio said a patient who was treated five years ago developed myelodysplastic syndrome, while another developed acute myeloid leukemia, The New York Times reported.
Though it is not yet clear what caused the cancers, one possibility is that the disabled virus used to deliver the gene therapy damaged crucial DNA in blood-forming cells in the patients' bone marrows. That would be the worst-case scenario, said John Tisdale, M.D., head of the cellular and molecular therapeutics branch at the National Heart, Lung, and Blood Institute.
But there is also the likelihood that both cancers were caused by a powerful drug, busulfan, which is used to clear bone marrow to make space for new cells modified by gene therapy. Busulfan is known to raise blood cancer risk, Tisdale noted.
Muddying the issue even further is the fact that people with sickle cell disease are known to have an increased risk for leukemia, even without treatment. Still, no one would expect two patients in a small trial to get the disease, The Times said.
© 2021 HealthDay. All rights reserved.
Posted: February 2021
Read this next
THURSDAY, Feb. 25, 2021 -- Black patients with hepatitis C virus (HCV) infection develop hepatocellular carcinoma (HCC) at an earlier disease stage and have better liver function...
THURSDAY, Feb. 25, 2021 -- For women aged younger than 65 years, the mortality gap between cancer and heart disease is narrowing, according to a study published online Feb. 8 in...
TUESDAY, Feb. 23, 2021 -- There has been a decline in vascular deaths among patients with diabetes, making cancer now the leading cause of death for these patients, according to a...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.